FDA Approves Amivantamab and Hyaluronidase-lpuj for Subcutaneous Injection By Ogkologos - January 14, 2026 82 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for safety and efficacy is based on the findings from the PALOMA-3 study Source RELATED ARTICLESMORE FROM AUTHOR Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours Rare Disease Day 2026: Advancing equity for people living with rare cancers in Europe EMA Recommends Extension of Therapeutic Indications for Ponatinib MOST POPULAR How Becky is helping her children to keep their dad’s memory... April 21, 2023 Nivolumab vs Sorafenib in First-Line Treatment of Advanced Hepatocellular Carcinoma July 1, 2020 Breast Cancer Vaccine Has Eliminated Cancer In Its First Human Patient December 16, 2019 Genomic Alterations Enriched in Young Women with HR-positive, HER2-negative Early Breast... February 9, 2023 Load more HOT NEWS FDA Approves First Adenoviral Vector-Based Gene Therapy for High-Risk Bacillus Calmette-Guérin... Girl’s New College Dorm Has Perfect View Of The Hospital Room... Significant iDFS Benefit with Adding Ribociclib to a Nonsteroidal Aromatase Inhibitor... Development of T-Cell Lymphoma After Chimeric Antigen Receptor T-Cell Therapy
